Methyldopa

Methyldopa, the active ingredient in this product, is an alpha‑2 adrenergic agonist presented as an oral formulation for systemic use. It is employed to lower high blood pressure, including hypertension during pregnancy, by reducing sympathetic nervous system activity.

GNH USA supplies this product as a licensed, GDP‑compliant international pharmaceutical supplier, adhering to stringent quality standards and regulatory requirements. The company provides reliable sourcing to hospitals, pharmacies and clinics worldwide, supporting consistent access to essential antihypertensive therapy across diverse markets globally.

Methyldopa is used to manage high‑blood‑pressure disorders by acting on central sympathetic pathways.

- Essential hypertension: reduces systolic and diastolic pressure in patients with primary high blood pressure. - Secondary hypertension: assists in controlling blood pressure when caused by underlying conditions. - Gestational hypertension: helps maintain safe maternal blood pressure levels during pregnancy.

Methyldopa may cause a range of adverse reactions, which vary in frequency and severity.

Common Side Effects: - Dizziness: sensation of light‑headedness, especially upon standing. - Headache: mild to moderate pain in the head region. - Fatigue: persistent tiredness or lack of energy. - Dry mouth: reduced salivation causing oral discomfort. - Nasal congestion: blockage or stuffiness of the nasal passages. - Sedation: feeling unusually sleepy or sluggish.

Serious or Rare Side Effects: - Hepatic dysfunction: signs of liver injury such as jaundice. - Hemolytic anemia: destruction of red blood cells leading to fatigue and pallor. - Severe hypotension: dangerously low blood pressure causing fainting. - Stevens‑Johnson syndrome: severe skin reaction with blistering. - Agranulocytosis: marked decrease in white blood cells, increasing infection risk.

When prescribing methyldopa, clinicians should consider several safety measures.

- Blood pressure monitoring: regularly assess to avoid excessive hypotension. - Liver function: evaluate hepatic enzymes before and during therapy. - Discontinuation: taper the dose gradually to prevent rebound hypertension. - Pheochromocytoma: avoid use in patients with catecholamine‑secreting tumors. - Depression: monitor for mood changes, as central agents may affect mental state. - Store at ambient temperature: keep below 25 °C in the original packaging, protect from moisture.

Methyldopa can interact with other medicines, influencing its efficacy or safety.

Major Interactions (Avoid): - MAO inhibitors: risk of severe hypertension when combined. - Sympathomimetic agents: may counteract the antihypertensive effect. - Other central α‑2 agonists: additive hypotensive response.

Moderate Interactions (Monitor Closely):\n- Diuretics: enhanced blood‑pressure lowering, requiring dose adjustment. - β‑blockers: potential for additive hypotension and bradycardia. - Lithium: possible increase in lithium levels, necessitating monitoring.